Innate Pharma S.A. Sponsored ADR (IPHA) – What Are Investment Firms Saying About This Stock?

Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA – Get Free Report) has earned a consensus rating of “Moderate Buy” from the six brokerages that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $6.67.

A number of research analysts have recently commented on IPHA shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Innate Pharma in a research report on Tuesday, September 22nd. Citigroup raised shares of Innate Pharma from a “buy” rating to an “outperform” rating in a report on Tuesday, August 11th. UBS Group reaffirmed a “buy” rating on shares of Innate Pharma in a research note on Tuesday, August 11th. Leerink Partners raised shares of Innate Pharma from a “market perform” rating to an “outperform” rating and set a $4.00 price target on the stock in a research note on Tuesday, August 11th. Finally, HC Wainwright reiterated a “buy” rating on shares of Innate Pharma in a report on Monday, September 21st.

Check Out Our Latest Report on Innate Pharma

Innate Pharma Stock Performance

NASDAQ IPHA opened at $1.03 on Thursday. Innate Pharma has a fifty-two week low of $1.00 and a fifty-two week high of $2.71. The business has a 50 day moving average price of $1.57 and a two-hundred day moving average price of $1.69.

Innate Pharma Company Profile

(Get Free Report)

Innate Pharma is a clinical-stage biotechnology company based in Marseille, France. It develops immunotherapies for cancer, with research focused on harnessing the body’s innate immune system to recognize and attack tumor cells. The company’s work includes antibody-based treatments and cell therapies, with investigational candidates being studied for blood cancers and other malignancies. Its pipeline includes lacutamab, an antibody candidate targeting KIR3DL2, and programs developed with pharmaceutical partners.

See Also

Analyst Recommendations for Innate Pharma (NASDAQ:IPHA)

Receive News & Ratings for Innate Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innate Pharma and related companies with MarketBeat.com's FREE daily email newsletter.